Jacobs Levy Equity Management, Inc Biocryst Pharmaceuticals Inc Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 247,795 shares of BCRX stock, worth $2.32 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
247,795
Previous 367,514
32.58%
Holding current value
$2.32 Million
Previous $2.79 Million
33.3%
% of portfolio
0.01%
Previous 0.01%
Shares
15 transactions
Others Institutions Holding BCRX
# of Institutions
277Shares Held
167MCall Options Held
728KPut Options Held
989K-
Vanguard Group Inc Valley Forge, PA21.9MShares$205 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$187 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$111 Million1.3% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$85 Million4.33% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$76.2 Million1.52% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.74B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...